Abstract
Diuretics are essential for the treatment of cardiac failure. Currently, carbonic anhydrase inhibitors, loop diuretics, thiazide diuretics and potassium sparing diuretics are generally used for diuretic therapy. However, their efficacy and issues have been pointed out, and the appropriate use of diuretics has been reported to influence the patient’s prognosis. Tolvaptan, a vasopressin V2 receptor antagonist, has drawn attention as a new diuretic in recent years. We will discuss various diuretics in this article.
